1. Home
  2. STXS vs MOLN Comparison

STXS vs MOLN Comparison

Compare STXS & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stereotaxis Inc.

STXS

Stereotaxis Inc.

HOLD

Current Price

$1.90

Market Cap

201.6M

Sector

Health Care

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

HOLD

Current Price

$4.34

Market Cap

158.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
STXS
MOLN
Founded
1990
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
201.6M
158.9M
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
STXS
MOLN
Price
$1.90
$4.34
Analyst Decision
Strong Buy
Buy
Analyst Count
2
2
Target Price
$4.00
$8.38
AVG Volume (30 Days)
396.1K
3.6K
Earning Date
06-08-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
16.67
N/A
EPS
N/A
N/A
Revenue
$29,346,617.00
N/A
Revenue This Year
$34.08
N/A
Revenue Next Year
$35.18
$318.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.54
$3.36
52 Week High
$3.59
$5.36

Technical Indicators

Market Signals
Indicator
STXS
MOLN
Relative Strength Index (RSI) 35.65 39.42
Support Level N/A $3.51
Resistance Level $2.52 $4.63
Average True Range (ATR) 0.12 0.26
MACD -0.01 -0.10
Stochastic Oscillator 10.10 19.05

Price Performance

Historical Comparison
STXS
MOLN

About STXS Stereotaxis Inc.

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: